Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-04

FDA Approved: VALTOCO — Supplemental Application (Neurelis, Inc)

View source ↗

Summary

The FDA approved a supplemental application for VALTOCO (diazepam) by Neurelis, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VALTOCO (diazepam nasal spray)

Snippet

SUPPL AP for VALTOCO (DIAZEPAM)